Rola N Hamam
American University of Beirut
Lebanon
Title: Uveitic macular edema: Pathophysiology and treatment update
Biography
Biography: Rola N Hamam
Abstract
Purpose: To review the epidemiology, risk factors and pathophysiology of uveitic macular edema and discuss advances in diagnosis and treatment Methods: Review of the literature and presentation of case series of the use of topical bromfenac for the treatment of uveitic macular edema, also discussion of the effect of intravitreal adalimumab on uveitic macular edema. Results: Advanced age and chronic edema are among the poor prognostic factors. 11 patients (14 eyes) treated with bromfenac 0.09% daily. Median CRT improved from 427 to 257 (p=0.002). 8/10 eyes had resolution of SRF. 6/11 eyes had resolution of CME. Median logMar improved from 0.39 to 0.17 (p=0.3) and 6/14 eyes gained more than 2 lines. 1.5 mg adalimumab injected intravitreally every month for active non infectious uveitis. 5/8 eyes had resolution of macular edema. Median time to resolution was 6 weeks (range: 2-26). Median CRT improved from 317 mm to 277 mm at 6 months (p=0.021).
